adalimumab-atto (Amjevita) vs infliximab-dyyb (Inflectra)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

infliximab-dyyb (Inflectra)

Marketed by Celltrion and partners

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02096861 · Phase 3 · completed

Randomized, double-blind Phase 3 non-inferiority trial of CT-P13 against originator infliximab in biologic-naive active Crohn's disease (n=220). The primary endpoint, CDAI-70 response at Week 6, met non-inferiority: the lower bound of the 95% CI (-16.9%) was above the -20% margin.

Next expected readout: December 2026 · NCT06064864 (registry estimate)

Reported efficacy

CDAI-70 response rate at Week 6: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin (met)

Result source: NCT02096861

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-atto (Amjevita)infliximab-dyyb (Inflectra)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not reported

Endoscopic response (induction)

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not reported

Clinical remission (maintenance)

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not reported

Endoscopic response (maintenance)

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-atto (Amjevita): no structured comparison results are available for Crohn's Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

infliximab-dyyb (Inflectra)
CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin NCT02096861 · Phase 3 · design grade: strong · publication or press release

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01970475 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)

Result source: NCT01970475

infliximab-dyyb (Inflectra)

Marketed by Celltrion and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01217086 · Phase 3 · completed

PLANETRA was a randomized, double-blind trial of CT-P13 against Remicade in active rheumatoid arthritis on methotrexate (617 enrolled; 606 in the ITT analysis). The published primary endpoint, ACR20 response at week 30, showed equivalence: 60.9% vs 58.6% (95% CI -6% to 10%), inside the predefined ±15% margin.

ClinicalTrials.gov lists pharmacokinetic equivalence as the primary outcome; the peer-reviewed PLANETRA report states the primary endpoint was ACR20 response at week 30.

Reported efficacy

ACR20 response at week 30 (equivalence vs Remicade, margin ±15%): ACR20 response at week 30 (ITT, n=606): CT-P13 60.9% vs innovator infliximab (INX) 58.6%; 95% CI −6% to 10%, within the predefined equivalence margin - equivalence demonstrated. (met)

Result source: NCT01217086

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-atto (Amjevita)infliximab-dyyb (Inflectra)
ACR2074.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
60.9% vs 58.6%avs innovator infliximab (INX)wk 30NCT01217086
ACR5049.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475—Not posted · NCT01217086
ACR7026% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475—Not posted · NCT01217086
DAS28-CRP remission—Not reported—Not posted · NCT01217086
HAQ-DI, change—Not reported—Not posted · NCT01217086
Modified Sharp score, change—Not reported—Not posted · NCT01217086

ACR20

adalimumab-atto (Amjevita)
74.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
infliximab-dyyb (Inflectra)
60.9% vs 58.6%avs innovator infliximab (INX)wk 30NCT01217086

ACR50

adalimumab-atto (Amjevita)
49.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475
infliximab-dyyb (Inflectra)
—Not posted · NCT01217086

ACR70

adalimumab-atto (Amjevita)
26% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475
infliximab-dyyb (Inflectra)
—Not posted · NCT01217086

DAS28-CRP remission

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not posted · NCT01217086

HAQ-DI, change

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not posted · NCT01217086

Modified Sharp score, change

adalimumab-atto (Amjevita)
—Not reported
infliximab-dyyb (Inflectra)
—Not posted · NCT01217086
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-atto (Amjevita): 4 of 4 rows · infliximab-dyyb (Inflectra): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-atto (Amjevita)infliximab-dyyb (Inflectra)
Dropout rate
8%a
NCT01970475 · Phase 3
—
Discontinued due to AEs
2.7%a
NCT01970475 · Phase 3
—
Serious AEs
3.8%a
NCT01970475 · Phase 3
—
Most frequent reported AEs
a
nasopharyngitis 6.4%
NCT01970475 · Phase 3
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-atto (Amjevita)

DAS28-CRP -1.01 vs -0.96 Adalimumab score @ 2wk
absolute change · score
NCT01970475 · Phase 3
show 5 more results
-1.45 vs -1.42 Adalimumab score @ 4wk
NCT01970475 · Phase 3
-1.79 vs -1.7 Adalimumab score @ 8wk
NCT01970475 · Phase 3
-2.04 vs -1.93 Adalimumab score @ 12wk
NCT01970475 · Phase 3
-2.3 vs -2.17 Adalimumab score @ 18wk
NCT01970475 · Phase 3
-2.32 vs -2.32 Adalimumab score @ 24wk
NCT01970475 · Phase 3
ACR50 49.2% (n=244) vs 52% (n=252) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3
ACR70 26% (n=246) vs 22.9% (n=253) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · infliximab-dyyb (Inflectra)'s landscape